Abstract Details

Title The Role of Ventriculo-Peritoneal Shunting (VPS) in Patients with Supratentorial Glioma

Topic Neuro-oncology

Presentation(s) IN10 - (-)

Poster/Presentation
Number 009

Objective

Background The role of VPS is uncertain in patients with glioma.

Design/Methods Retrospective review of patients with glioma who had a VPS between January 1995 to February 2012.

Results We identified 2522 patients diagnosed with grade II-IV glioma of whom 41 (1.62%) had VPS placement. 25 were men and median age was 58 (range, 20-73 years). 23 patients had grade IV, 15 grade III and 3 grade II glioma. All had surgical resection, 20 had a second and 7 a third resection; the lateral ventricle was opened in 16 (39%). All patients received RT. At time of VPS all were symptomatic, 28 had cognitive impairment, 26 gait disturbance and 7 urinary incontinence; 8 had atypical symptoms. Ventriculomegaly was observed in 38 patients (93%) and leptomeningeal disease (LMD) in 9. Median time from glioma diagnosis to VPS placement was 10 months (range 1 -252 months). 26 (63%) improved after VPS. The median OS VPS shunting was 6 months for all patients but was 11 months for those who improved. Median OS for the non-responder group was 3 months. None of the following parameters predicted improvement after VPS: age, classical symptoms, LMD or glioma grade. Increased number of surgeries was associated with worse outcome; patients who underwent a third surgery had a median OS of 2.5 months after VPS. 15 (36%) developed post-surgical complications.

Conclusions The majority of patients improved after VPS and had better OS. However, age, classical symptoms, LMD or glioma grade could not predict benefit. An increased number of surgeries is associated with worse outcome, but patients who improved after VPS placement have a prolonged OS.

Authors/Disclosures
Macarena De La Fuente, MD (University of Miami) PRESENTER	Dr. De La Fuente has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier Pharmaceuticals. Dr. De La Fuente has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pyramid Biosciences. An immediate family member of Dr. De La Fuente has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. An immediate family member of Dr. De La Fuente has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ADC Therapeutics.
Lisa M. DeAngelis, MD, FAAN (Memorial Sloan-Kettering Cancer Center)	Dr. DeAngelis has received publishing royalties from a publication relating to health care.
Andrew H. Evans, MB, BS	Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie. Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stada. Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Seqirus. Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen. Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie. Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Stada. The institution of Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Ipsen. Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Seqirus.

��ɫ��

��ɫ��